"It’s very fulfilling to work at a place like Genentech where I am constantly inspired to grow and innovate."
I joined the Antibody Engineering Department at Genentech in 2020 after completing my postdoctoral work at UCSF where I investigated antibody-based strategies to target disease-specific neo-epitopes. Prior to this, I completed my graduate studies at UC Berkeley in protein biophysics.
I was drawn to Genentech because I wanted to be part of a scientific community with a strong commitment and proven track-record for delivering life-changing medicines for patients. I feel incredibly fortunate to collaborate with talented colleagues across the organization to discover and engineer the next generation of biotherapeutics.
2022, Advanced Drug Delivery Reviews, 182, 114112.
2022, Journal of Clinical Investigation, 132, e154604.
My group is interested in discovering and engineering novel antibody and protein-based molecules to enable the next generation of biotherapeutics and biological tools. We are interested in expanding beyond the traditional antibody scaffold and building novel functionalities and mechanisms of actions into these molecules. By doing so, we hope to expand the targetable space, enable exquisite specificity for safer and more effective therapies, and endow molecules with unique properties to address limitations of existing drugs. We are also excited about leveraging AI/ML and computational tools to accelerate the drug discovery process. The projects in my group require active collaboration with researchers across Large Molecule Drug Discovery, the various Therapeutic Areas, and throughout the research organization.